Sio Gene Therapies Email Format

Biotechnology ResearchNew York, United States51-200 Employees

Sio Gene Therapies is a biotechnology company focused on developing genetic medicines through gene therapy, aiming to radically improve patient outcomes. Its clinical pipeline centers on gene therapies intended for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, rare pediatric conditions caused by single-gene defects, with potential for curative benefit. The company is also pursuing applications for more prevalent disorders such as Parkinson's disease to broaden the reach of gene therapy. Headquartered in New York City, New York, the company operates as a mid-sized biotechnology firm supported by collaborations with academic, industry, and patient advocacy groups. Its activities place it in the clinical-stage segment of biotechnology, and it has engaged in partnerships and program updates over time, including a 2020 collaboration with Invitae to offer genetic testing for pediatric lysosomal storage diseases.

Sign up for free to view info

Company overview Employee directory